Who are Miltefosine and Paromomycin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): miltefosine + Paromomycin sulfate, IDA - Ivermectin + DEC + albendazole, Ambisome and Paromomycin, liposomal amphotericin B + paromomycin, Liposomal Amphotericin B with Miltefosine, Ambisome + Miltefosine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/miltefosine-and-paromomycin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Miltefosine and Paromomycin — Competitive Intelligence Brief

Miltefosine and Paromomycin (Miltefosine and Paromomycin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiparasitic combination. Area: Infectious Disease / Neglected Tropical Diseases.

phase 3 Antiparasitic combination Leishmania cell membrane and ribosomal protein synthesis Infectious Disease / Neglected Tropical Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Miltefosine and Paromomycin (Miltefosine and Paromomycin) — Drugs for Neglected Diseases. Miltefosine disrupts parasite cell membranes while paromomycin inhibits protein synthesis, together providing synergistic activity against Leishmania parasites.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Miltefosine and Paromomycin TARGET	Miltefosine and Paromomycin	Drugs for Neglected Diseases	phase 3	Antiparasitic combination	Leishmania cell membrane and ribosomal protein synthesis
miltefosine + Paromomycin sulfate	miltefosine + Paromomycin sulfate	Banaras Hindu University	phase 3	Antiparasitic combination therapy	Leishmania cell membrane and ribosomal protein synthesis
IDA - Ivermectin + DEC + albendazole	IDA - Ivermectin + DEC + albendazole	Medicines Development for Global Health	phase 3	Antiparasitic combination	GABA-gated chloride channels (ivermectin); β-tubulin (albendazole); microfilarial motility (DEC)
Ambisome and Paromomycin	Ambisome and Paromomycin	Drugs for Neglected Diseases	phase 3	Antifungal and antiparasitic combination	Fungal ergosterol; parasitic 30S ribosomal subunit
liposomal amphotericin B + paromomycin	liposomal amphotericin B + paromomycin	Drugs for Neglected Diseases	phase 3	Antifungal/antiparasitic combination	Ergosterol (amphotericin B); ribosomal protein synthesis (paromomycin)
Liposomal Amphotericin B with Miltefosine	Liposomal Amphotericin B with Miltefosine	Banaras Hindu University	phase 3	Antifungal/antiparasitic combination	Fungal ergosterol; phosphatidylcholine synthesis pathway
Ambisome + Miltefosine	Ambisome + Miltefosine	Drugs for Neglected Diseases	phase 3	Antifungal/antiparasitic combination	Ergosterol (amphotericin B); phosphatidylcholine synthesis pathway (miltefosine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiparasitic combination class)

Drugs for Neglected Diseases · 1 drug in this class
Medicines Development for Global Health · 1 drug in this class
University Hospitals Cleveland Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Miltefosine and Paromomycin — Competitive Intelligence Brief. https://druglandscape.com/ci/miltefosine-and-paromomycin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab